Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2019-02-14 Major Shareholding Noti…
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
CONSONANCE CAPITAL MANAGEMENT LP
Major Shareholding Notification
2019-02-14 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is reporting "Other Events" related to a press release about updated clinical data from a Phase IIb study. There are no financial statements or detailed financial data included, and the document is relatively short (3438 characters). It primarily serves as an announcement of an event rather than a detailed financial or management report. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2019-02-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 4, 2019. It reports an event under Item 8.01 'Other Events' and includes a press release announcing the first patient treated in a clinical trial. The document is short (3448 characters) and primarily serves as a current report to disclose a specific event rather than detailed financial data or comprehensive reporting. It does not contain financial statements or detailed analysis but rather an announcement of a significant company event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-02-04 English
PRIMARY DOCUMENT
Director's Dealing
2019-01-31 English
PRIMARY DOCUMENT
Director's Dealing
2019-01-31 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.